The polyamino-isoprenyl enhancer NV716 enables the antibacterial activity of two families of multi-target inhibitors against the ESKAPEE bacterium Enterobacter cloacae

Abstract

Gram-negative bacteria are particularly prone to developing antimicrobial resistance (AMR), as evidenced by the WHO's ESKAPEE list of high-priority pathogens. One strategy that has increased is the use of antibiotic enhancers, which can re-empower abandoned or poorly active antibiotics against the resistant strain of interest. In this study, the polyamino-isoprenyl antibiotic enhancer, NV716, was tested in combination with two families of multi-target Ser/Cys-based enzyme inhibitors, the oxadiazolone derivatives (OX) and the Cyclipostins and Cyclophostin analogs (CyC), which are inactive against Gram-negative ESKAPEE bacteria, to potentiate their antibacterial activity and thus make them active against these bacteria. We demonstrated that NV716 potentiates some OX and CyC compounds by permeabilizing the outer membrane and thus by increasing the inhibitor accumulation, as shown by fluorescence microscopy. By using the click-chemistry activity-based protein profiling (ABPP) approach coupled with proteomic analysis, we also confirmed the multi-target nature of the best OX and CyC inhibitors by identifying their target proteins on a bacterial culture of Enterobacter cloacae. Remarkably, a large set of these identified proteins had already been captured in previous ABPP experiments conducted on Mycobacterium tuberculosis and/or Mycobacterium abscessus culture. Furthermore, we showed that five of the identified target proteins were present in a total lysate of Pseudomonas aeruginosa. Importantly, these latter enzymes are highly conserved among Gram-negative bacteria, with two of them annotated as essential for bacterial survival. These results provide proof of concept that both OX and CyC, if successfully potentiated, could be used against ESKAPEE Gram-negative bacteria.

Keywords

activity based-protein profiling / antibiotic resistance / Cyclipostins and Cyclophostin analogs / drug enhancers / oxadiazolone derivatives

References

[1] Cook MA, Wright GD. The past, present, and future of antibiotics. Sci Transl Med. 2022; 14: eabo7793.

[2] Aminov RI. A brief history of the antibiotic era: lessons learned and challenges for the future. Front Microbiol. 2010; 1: 134.

[3] O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. The Review on Antimicrobial Resistance. 2016. Available from: https://amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf

[4] Murray C, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022; 399: 629-655.

[5] WHO. WHO publishes list of bacteria for which new antibiotics are urgently needed. 2017 [cited 2024 Aug 20]. Available from: https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed

[6] WHO. WHO bacterial priority pathogens list, 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance 2024 [cited 2024 Dec 19]. Available from: https://www.who.int/publications/i/item/9789240093461

[7] De Oliveira DMP, Forde BM, Kidd TJ, Harris PNA, Schembri MA, Beatson SA, et al. Antimicrobial resistance in ESKAPE pathogens. Clin Microbiol Rev. 2020; 33: e00181-19.

[8] Mancuso G, Midiri A, Gerace E, Biondo C. Bacterial antibiotic resistance: the most critical pathogens. Pathogens. 2021; 10: 1310.

[9] Beveridge TJ. Structures of Gram-negative cell walls and their derived membrane vesicles. J Bacteriol. 1999; 181: 4725-4733.

[10] Delcour AH. Outer membrane permeability and antibiotic resistance. Biochim Biophys Acta. 2009; 1794: 808-816.

[11] Li XZ, Plésiat P, Nikaido H. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin Microbiol Rev. 2015; 28: 337-418.

[12] Wright GD. Antibiotic adjuvants: rescuing antibiotics from resistance. Trends Microbiol. 2016; 24: 862-871.

[13] Douafer H, Andrieu V, Phanstiel O, Brunel JM. Antibiotic adjuvants: make antibiotics great again! J Med Chem. 2019; 62: 8665-8681.

[14] Docquier JD, Mangani S. An update on β-lactamase inhibitor discovery and development. Drug Resist Updat. 2018; 36: 13-29.

[15] Dhanda G, Acharya Y, Haldar J. Antibiotic adjuvants: a versatile approach to combat antibiotic resistance. ACS Omega. 2023; 8: 10757-10783.

[16] Pieren M, Tigges M. Adjuvant strategies for potentiation of antibiotics to overcome antimicrobial resistance. Curr Opin Pharmacol. 2012; 12: 551-555.

[17] Lieutaud A, Pieri C, Bolla JM, Brunel JM. New polyaminoisoprenyl antibiotics enhancers against two multidrug-resistant Gram-negative bacteria from enterobacter and salmonella species. J Med Chem. 2020; 63: 10496-10508.

[18] Draveny M, Rose C, Pinet A, Ferrié L, Figadère B, Brunel J-M, et al. Scope and limitations of exploiting the ability of the chemosensitizer NV716 to enhance the activity of tetracycline derivatives against Pseudomonas aeruginosa. Molecules. 2023; 28: 4262.

[19] Delorme V, Diomandé SV, Dedieu L, Cavalier JF, Carrière F, Kremer L, et al. MmPPOX inhibits Mycobacterium tuberculosis lipolytic enzymes belonging to the hormone-sensitive lipase family and alters mycobacterial growth. PLoS One. 2012; 7: e46493.

[20] Nguyen PC, Delorme V, Bénarouche A, Guy A, Landry V, Audebert S, et al. Oxadiazolone derivatives, new promising multi-target inhibitors against M. tuberculosis. Bioorg Chem. 2018; 81: 414-424.

[21] Point V, Malla RK, Diomande S, Martin BP, Delorme V, Carriere F, et al. Synthesis and kinetic evaluation of cyclophostin and cyclipostins phosphonate analogs as selective and potent inhibitors of microbial lipases. J Med Chem. 2012; 55: 10204-10219.

[22] Madani A, Ridenour JN, Martin BP, Paudel RR, Abdul Basir A, Le Moigne V, et al. Cyclipostins and cyclophostin analogues as multitarget inhibitors that impair growth of mycobacterium abscessus. ACS Infect Dis. 2019; 5: 1597-1608.

[23] Spilling CD. The chemistry and biology of cyclophostin, the cyclipostins and related compounds. Molecules. 2019; 24: 2579.

[24] Wang G, Brunel JM, Rodriguez-Villalobos H, Bolla JM, Van Bambeke F. The polyamino-isoprenyl potentiator NV716 revives disused antibiotics against Gram-negative bacteria in broth, infected monocytes, or biofilms, by disturbing the barrier effect of their outer membrane. Eur J Med Chem. 2022; 238: 114496.

[25] Troudi A, Fethi M, Selim El Asli M, Bolla JM, Klibi N, Brunel JM. Efficiency of a tetracycline-adjuvant combination against multidrug resistant Pseudomonas aeruginosa Tunisian clinical isolates. Antibiotics. 2020; 9: 919.

[26] Wang G, Brunel JM, Bolla JM, Van Bambeke F. The polyaminoisoprenyl potentiator NV716 revives old disused antibiotics against intracellular forms of infection by Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2021; 65: e02028-20.

[27] Gray DA, Wenzel M. Multitarget approaches against multiresistant superbugs. ACS Infect Dis. 2020; 6: 1346-1365.

[28] Huemer M, Mairpady Shambat S, Brugger SD, Zinkernagel AS. Antibiotic resistance and persistence-implications for human health and treatment perspectives. EMBO Rep. 2020; 21: e51034.

[29] Uddin TM, Chakraborty AJ, Khusro A, Zidan BRM, Mitra S, Emran TB, et al. Antibiotic resistance in microbes: history, mechanisms, therapeutic strategies and future prospects. J Infect Public Health. 2021; 14: 1750-1766.

[30] Cavalier JF, Spilling CD, Durand T, Camoin L, Canaan S. Lipolytic enzymes inhibitors: a new way for antibacterial drugs discovery. Eur J Med Chem. 2021; 209: 112908.

[31] Madani A, Mallick I, Guy A, Crauste C, Durand T, Fourquet P, et al. Dissecting the antibacterial activity of oxadiazolone-core derivatives against Mycobacterium abscessus. PLoS One. 2020; 15: e0238178.

[32] Nguyen PC, Delorme V, Bénarouche A, Martin BP, Paudel R, Gnawali GR, et al. Cyclipostins and cyclophostin analogs as promising compounds in the fight against tuberculosis. Sci Rep. 2017; 7: 11751.

[33] Barelier S, Avellan R, Gnawali GR, Fourquet P, Roig-Zamboni V, Poncin I, et al. Direct capture, inhibition and crystal structure of HsaD (Rv3569c) from M. tuberculosis. FEBS J. 2023; 290: 1563-1582.

[34] Nguyen PC, Madani A, Santucci P, Martin BP, Paudel RR, Delattre S, et al. Cyclophostin and Cyclipostins analogues, new promising molecules to treat mycobacterial-related diseases. Int J Antimicro Agents. 2018; 51: 651-654.

[35] Sarrazin M, Martin BP, Avellan R, Gnawali GR, Poncin I, Le Guenno H, et al. Synthesis and biological characterization of fluorescent cyclipostins and cyclophostin analogues: new insights for the diagnosis of mycobacterial-related diseases. ACS Infect Dis. 2022; 8: 2564-2578.

[36] Weseler A, Geiss HK, Saller R, Reichling J. A novel colorimetric broth microdilution method to determine the minimum inhibitory concentration (MIC) of antibiotics and essential oils against Helicobacter pylori. Pharmazie. 2005; 60: 498-502.

[37] Tunney MM, Ramage G, Field TR, Moriarty TF, Storey DG. Rapid colorimetric assay for antimicrobial susceptibility testing of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2004; 48: 1879-1881.

[38] Borselli D, Brunel JM, Gorgé O, Bolla JM. Polyamino-isoprenyl derivatives as antibiotic adjuvants and motility inhibitors for Bordetella bronchiseptica porcine pulmonary infection treatment. Front Microbiol. 2019; 10: 1771.

[39] Troudi A, Bolla JM, Klibi N, Brunel JM. An original and efficient antibiotic adjuvant strategy to enhance the activity of macrolide antibiotics against Gram-negative resistant strains. Int J Mol Sci. 2022; 23: 12457.

[40] Wang G, Brunel JM, Preusse M, Mozaheb N, Willger SD, Larrouy-Maumus G, et al. The membrane-active polyaminoisoprenyl compound NV716 re-sensitizes Pseudomonas aeruginosa to antibiotics and reduces bacterial virulence. Commun Biol. 2022; 5: 871.

[41] Ferrand A, Vergalli J, Bosi C, Pantel A, Pagès JM, Davin-Regli A. Contribution of efflux and mutations in fluoroquinolone susceptibility in MDR enterobacterial isolates: a quantitative and molecular study. J Antimicrob Chemother. 2023; 78: 1532-1542.

[42] Schindler PRG, Teuber M. Action of polymyxin B on bacterial membranes: morphological changes in the cytoplasm and n the outer membrane of Salmonella typhimurium and Escherichia coli B. Antimicrob Agents Chemother. 1975; 8: 95-104.

[43] Sautrey G, El Khoury M, Dos Santos AG, Zimmermann L, Deleu M, Lins L, et al. Negatively charged lipids as a potential target for new amphiphilic aminoglycoside antibiotics. J Biol Chem. 2016; 291: 13864-13874.

[44] Cabrini G, Verkman AS. Potential-sensitive response mechanism of diS-C3-(5) in biological membranes. J Membr Biol. 1986; 92: 171-182.

[45] Borselli D, Lieutaud A, Thefenne H, Garnotel E, Pagès JM, Brunel JM, et al. Polyamino-isoprenic derivatives block intrinsic resistance of P. aeruginosa to doxycycline and chloramphenicol in vitro. PLoS One. 2016; 11: e0154490.

[46] Bohnert JA, Schuster S, Szymaniak-Vits M, Kern WV. Determination of real-time efflux phenotypes n Escherichia coli AcrB binding pocket phenylalanine mutants using a 1,2'-dinaphthylamine efflux assay. PLoS One. 2011; 6: e21196.

[47] Blair JMA, Piddock LJV. How to measure export via bacterial multidrug resistance efflux pumps. mBio. 2016; 7: e00840-16.

[48] Piddock LJV. Multidrug-resistance efflux pumps—not just for resistance. Nat Rev Microbiol. 2006; 4: 629-636.

[49] Larson G. Some aspects of the chemistry of alkynylsilanes. Synthesis. 2018; 50: 2433-2462.

[50] Panichakul D, Lim YW, Mathey F. Reactivity of 2-silyl- and 2-stannyl-substituted phosphirenes. Organometallics. 2010; 29: 1985-1987.

[51] Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, Kanehisa M. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 1999; 27: 29-34.

[52] Kanehisa M, Sato Y, Kawashima M, Furumichi M, Tanabe M. KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 2016; 44: D457-D462.

[53] Díez-González S. Chapter Three—Copper(I)-acetylides: access, structure, and relevance in catalysis. In: Pérez PJ editor, Advances in organometallic chemistry. 66, London: Academic Press; 2016. p. 93-141.

[54] Whiteside MD, Winsor GL, Laird MR, Brinkman FSL. OrtholugeDB: a bacterial and archaeal orthology resource for improved comparative genomic analysis. Nucleic Acids Res. 2013; 41: D366-D376.

[55] Luo H, Lin Y, Gao F, Zhang CT, Zhang R. DEG 10, an update of the database of essential genes that includes both protein-coding genes and noncoding genomic elements. Nucleic Acids Res. 2014; 42: D574-D580.

[56] Brogden RN, Carmine A, Heel RC, Morley PA, Speight TM, Avery GS. Amoxycillin/clavulanic acid: a review of its antibacterial activity, pharmacokinetics and therapeutic use. Drugs. 1981; 22: 337-362.

[57] Stokes JM, MacNair CR, Ilyas B, French S, Côté JP, Bouwman C, et al. Pentamidine sensitizes Gram-negative pathogens to antibiotics and overcomes acquired colistin resistance. Nat Microbiol. 2017; 2: 17028.

[58] MacNair CR, Farha MA, Serrano-Wu MH, Lee KK, Hubbard B, Côté JP, et al. Preclinical development of pentamidine analogs identifies a potent and nontoxic antibiotic adjuvant. ACS Infect Dis. 2022; 8: 768-777.

[59] Zurawski DV, Reinhart AA, Alamneh YA, Pucci MJ, Si Y, Abu-Taleb R, et al. SPR741, an antibiotic adjuvant, potentiates the in vitro and in vivo activity of rifampin against clinically relevant extensively drug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2017; 61: e01239-17.

[60] Vaara M. Polymyxin derivatives that sensitize Gram-negative bacteria to other antibiotics. Molecules. 2019; 24: 249.

[61] Eckburg PB, Lister T, Walpole S, Keutzer T, Utley L, Tomayko J, et al. Safety, tolerability, pharmacokinetics, and drug interaction potential of SPR741, an intravenous potentiator, after single and multiple ascending doses and when combined with β-lactam antibiotics In healthy subjects. Antimicrob Agents Chemother. 2019; 63: e00892-19.

[62] Krishnamoorthy G, Leus IV, Weeks JW, Wolloscheck D, Rybenkov VV, Zgurskaya HI. Synergy between active efflux and outer membrane diffusion defines rules of antibiotic permeation into Gram-negative bacteria. mBio. 2017; 8: e01172-17.

[63] Wesseling CMJ, Martin NI. Synergy by perturbing the Gram-negative outer membrane: opening the door for Gram-positive specific antibiotics. ACS Infect Dis. 2022; 8: 1731-1757.

[64] Hansen LH, Jensen LB, Sørensen HI, Sørensen SJ. Substrate specificity of the OqxAB multidrug resistance pump in Escherichia coli and selected enteric bacteria. J Antimicrob Chemother. 2007; 60: 145-147.

[65] Chiaradia L, Lefebvre C, Parra J, Marcoux J, Burlet-Schiltz O, Etienne G, et al. Dissecting the mycobacterial cell envelope and defining the composition of the native mycomembrane. Sci Rep. 2017; 7: 12807.

[66] Daffé M, Marrakchi H. Unraveling the structure of the mycobacterial envelope. Microbiol Spectr. 2019; 7: e0027-2018.

[67] Gutsmann T, Hagge SO, David A, Roes S, Böhling A, Hammer MU, et al. Lipid-mediated resistance of Gram-negative bacteria against various pore-forming antimicrobial peptides. J Endotoxin Res. 2005; 11: 167-173.

[68] Deutsch EW, Bandeira N, Sharma V, Perez-Riverol Y, Carver JJ, Kundu DJ, et al. The ProteomeXchange consortium in 2020: enabling 'big data' approaches in proteomics. Nucleic Acids Res. 2020; 48: 1145.

[69] Perez-Riverol Y, Bai J, Bandla C, García-Seisdedos D, Hewapathirana S, Kamatchinathan S, et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. Nucleic Acids Res. 2022; 50: D543-D552.

RIGHTS & PERMISSIONS

2025 The Author(s). mLife published by John Wiley & Sons Australia, Ltd on behalf of Institute of Microbiology, Chinese Academy of Sciences.